StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) company profile

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3028% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

About Vir Biotechnology

Biological Products, (No Diagnostic Substances), SIC 2836

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for serious infectious diseases and cancer. The company utilizes proprietary artificial intelligence antibody engineering and masked T-cell engager platforms to create treatments that enhance immune responses against life-threatening illnesses. Its clinical pipeline includes investigational therapies for chronic hepatitis delta, specifically the combination of tobevibart and elebsiran, as well as T-cell engagers targeting solid tumors, including metastatic castration-resistant prostate cancer, HER2-expressing cancers, and EGFR-expressing cancers. Vir Bio also researches preclinical antibody candidates for HIV, influenza, and coronaviruses. The company targets patients suffering from severe medical conditions with limited therapeutic options, collaborating with global health foundations and commercial biopharmaceutical partners.

The company conducts clinical trials and establishes international licensing arrangements across various regions, including the United States, Europe, Australia, New Zealand, and Greater China. Vir Bio maintains internal process and analytical development facilities while utilizing external contract development and manufacturing organizations to advance its pipeline. The company's headquarters are not stated in the provided text.

Summary of the business section of Vir Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
Vir Biotechnology, Inc.
Founded
2016
Headquarters
San Francisco, CA
Address
1800 Owens Street, Suite 900 94158
Phone
(415) 906-4324
Employees
367, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
VIR
Exchange
Nasdaq
IPO date
Oct 11, 2019
Shares outstanding
169M, Jul 29, 2026
Public float
$689.20M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1706431
CUSIP
92764N102
ISIN
US92764N1028
FIGI
BBG00H2QQ8T5
Share class FIGI
BBG00H2QQ8V2
EIN
81-2730369

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Backer Marianne DePresident and CEO, Director1,001,263
Aziz SawafEVP, Chief Financial Officer75,000
Brent SabatiniSVP, Chief Accounting Officer111,902
Verneuil Vanina deEVP, General Counsel, Corp Sec110,193
Jason O'ByrneEVP & Chief Financial Officer162,615
Mark EisnerEVP and Chief Medical Officer154,024
Ann M. HanlyEVP & Chief Technology Officer117,913
Suzanne Louise TopalianDirector12,731
Robert J. MoreDirector558,573
Timothy CoughlinDirector0
Janet NapolitanoDirector21,216
Jeffrey S. HatfieldDirector39,806
Norbert W. BischofbergerDirector32,000
Charles Elliott SigalDirector49,806
Ramy FaridDirector32,000
Vicki L. SatoDirector1,078,391
Saira RamasastryDirector22,619
George A. ScangosDirector1,849,969

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.83M$3.10M$2.00M$23$125
FY2024
Dr.De Backer
$9.26M$3.99M$1.90M$27$93
FY2024
Dr.Scangos
$0$0$1.90M$27$93
FY2023
Dr De Backer
$39.49M$18.21M$3.53M$38$94
FY2023
Dr Scangos
$338.20K-$4.72M$3.53M$38$94
FY2023
Dr.De Backer
$39.49M$18.21M$3.53M$38$94

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Marianne De Backer
President, Chief Executive Officer and Director
$950.00K–$2.30M$3.51M$1.00M$77.14K$7.83M-15%
Vanina de Verneuil
Executive Vice President, General Counsel and Corporate Secretary
$506.33K–$334.95K$511.49K$329.65K$8.36K$1.69M+1%
Mark Eisner
Executive Vice President and Chief Medical Officer
$660.83K$375.00K$382.80K$584.56K$354.29K$14.00K$2.37M-14%
Jason O’Byrne
Executive Vice President and Chief Financial Officer
$534.42K$150.00K$382.80K$584.56K$286.05K$14.00K$1.95M+2%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 11, 2019
Offer price
$20.00
Securities offered
7,142,858
Gross proceeds
$142.86M
Exchange
Nasdaq
First trading day
Oct 11, 2019
First-day close
$14.02-29.9%
Lock-up ends (est.)
Apr 8, 2020

“The initial public offering price per share is $20.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 367 employees, 282 of whom were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?